The aim of the study was to assess indicator condition (IC) guided HIV testing in Estonia from 2012-2015.
Introduction
Routine HIV testing in patients presenting with diseases/ conditions which may indicate the presence of HIV infection, the so-called indicator conditions (IC), has been recommended to increase the HIV detection rate [1, 2] . One advantage of IC-guided HIV testing is the removal of the need for an HIV risk assessment, as the IC itself acts as a trigger for the routine offer of an HIV test, independent of other risk factors [3] . The IC-guided approach has been included in HIV testing guidance in many European countries [4] , however testing rates of patients presenting with IC remain low in many settings studied [3, 5, 6] .
Estonia, located in North-Eastern Europe, has a total population of approximately 1.3 million people [7] and the highest rate of newly diagnosed HIV cases in the European Union (20.6 cases per 100 000 population in 2015) [8] . HIV testing has been available since 1987 and any doctor in Estonia (either a general practitioner or a specialist) can recommend HIV testing based on clinical indications, risk assessment or the patient's request [9] . The latest national guidance for provider initiated testing and counselling took effect in 2012. The main groups for whom HIV testing is recommended include people with HIV indicator diseases and conditions, people who have injected drugs or engaged in risky sexual behaviour, pregnant women, and prisoners. In the two regions with the highest HIV incidence, HIV testing is recommended to all patients aged 16-49 years [10] . In regards to IC-guided HIV testing, data from the National Tuberculosis Registry indicates that the percentage of new and relapsed tuberculosis cases who have been tested for HIV has increased from 91% in 2005 to 96% in 2013 [11] . However, there is no other available data on IC-guided HIV testing rates in Estonia.
The aim of this study was to assess IC-guided HIV testing among people aged 15-49 in Estonia using data from the Estonian Health Insurance Fund (EHIF).
Methods
Data was collected from EHIF's database of treatment invoices. EHIF is the core purchaser of health care services in Estonia, covering health care costs for insured people (94% of the total population). After health care services' provision, the provider sends an invoice to EHIF, which includes patient information (e.g. age, gender, diagnoses based on ICD-10) and services provided (what tests were performed, etc.)
We derived cumulative data (by gender and 5-year age groups) on people aged 15-49 who had received inpatient or outpatient (both primary and specialist) health care services at least once from 2012-2015. The analysis is person-based and every person is included only once despite the number of invoices they had per IC case.
The diagnoses on treatment invoices are categorized as HIV ICs as recommended by the HIV in Europe Initiative [2] :
• Sexually transmitted infections (STI): A51-A52 (syphilis), A54 (gonorrhoea), A56 (Chlamydia), A59 (trichomoniasis), A60 (herpes simplex);
• B02 (herpes zoster); • B27 (infectious mononucleosis); • B16-B18 (acute and chronic viral hepatitis);
• J12-J18 (pneumonia). Table 1 shows the proportion of patients aged 15-49 -separated by gender -presenting with HIV ICs who received an HIV test in 2012-2015. Among the ICs analysed, the highest proportion of patients tested was among those with infectious mononucleosis-like illness (27-33% of patients) and viral hepatitis (28-32%), the lowest proportion of patients tested was found among those with herpes zoster (4-5%) and pneumonia (4-8%). In general, women were tested somewhat less than men. The largest differences by gender appeared in STIs (9-13% of women and 18-21% of men were tested) ( Table 2 ).
Results

Discussion
IC-guided HIV testing is an acceptable, feasible and effective strategy to address the on-going HIV epidemic in Europe, and widely applied it may reduce the level of undiagnosed HIV infection and facilitate earlier diagnosis [12, 13] . In Estonia, IC-guided testing has been included in national guidance since 2012, but many professional societies had already endorsed it earlier. Despite that, our results reveal that only some patients presenting with the ICs under study were tested for HIV (generally less than one third). Over the 4 year period studied (2012-2015), testing rates have not increased, thus showing that existing testing guidance is not followed. The strength of our analysis is that it includes almost nation-wide coverage and draws on stable data collection methods.
Women with ICs were tested somewhat less than men, especially in case of STIs. It is difficult to interpret this result. One reason might be the perceived risk of HIV. In Estonia, around 70% of HIV cases have been diagnosed in men [14] and men might be perceived to be at higher risk for HIV. For example in 2015, 45% of all new HIV cases were diagnosed among men older than 29 years of age [14] . At the same time, STIs have a very different population distribution. Approximately 90% of all reported STIs in Estonia are Chlamydia cases (in 2015, the rate was 103 per 100 000 population) and approximately 80% of all Chlamydia cases are among women aged 15-29 [15, 16] . Another reason might lie with the speciality and practices of the doctors. Many women in the age-group under study are tested for HIV during pregnancy and the HIV-test results are known by the gynaecologists who usually also treat STIs in women. On the other hand, men generally attend dermatovenerologists for STI care.
Patients presenting with viral hepatitis and infectious mononucleosis-like illness were tested more than those with pneumonia or herpes zoster. The first two conditions are generally treated by specialist doctors (e.g., infectious diseases specialists who also treat HIV), the latter two by family doctors (primary care). HIV-testing in primary care has been very limited in general. Even among 15-49 year old patients accessing primary care in two Estonian regions where testing is recommended to everybody in this age-group, HIV testing rates remained below 2% in 2012-2015 [17] .
Our data have several limitations. The EHIF database's primary function is to track health care costs not necessarily to provide information on the quality of health care. ICs as well as HIV-tests may have been miscoded on treatment invoices. We use the ICD-10 diagnosis codes as proxies for the conditions. For example, code B27 is a proxy for mononucleosis-like illness. This is a limitation to the data because not all patients presenting with mononucleosis-like symptoms actually have infectious mononucleosis. Not all cases coded as B27 have been confirmed in a lab, but some might be based on clinical diagnosis. On the other hand, it may also happen that patients with laboratory confirmed infectious mononucleosis may have other ICD-10 codes on their invoices (e.g. B34 -viral infection of unspecified site) and will then not necessarily be captured by code B27. The extent of this misclassification is difficult to estimate and is a limitation to using ICD codes to monitor total test rates in patients presenting with mononucleosis-like illness.
HIV tests can be marked on the invoice not only as an "HIV test" but also as a "Detection of infection marker using immunological methods". The price for these two tests has always been the same, thus for tracking of health care costs it has not been important to distinguish which one is marked on the invoice. This misclassification would tend to increase rather than decrease the proportion tested.
We have no data on previous HIV testing of these patients. For example, people with chronic viral hepatitis [9] . This would also increase rather than decrease the proportion tested among patients with chronic hepatitis. Among other patients, the earlier diagnosis of HIV-infection would not have such large influence, if we assume that the HIV prevalence rate is more or less comparable to the prevalence in the general population (1.3% in 2013 [18] ). We have no data on private health care services (paid by patients themselves or by other insurance companies) and HIV-testing in the framework of them. Private health care services in Estonia are mostly visited by people who are able to pay for health care. 94% of the population has national health insurance. Uninsured people are mostly men aged 20-59 who are long-term unemployed or work unofficially [19] . They can also receive free of charge health care, including an HIV test, if their health condition requires it. Considering this, we estimate that the proportion of private health care services is small.
Despite these limitations we conclude that insurance data can be used to monitor HIV testing trends. Our data indicate low levels of IC-guided HIV testing in Estonia. Therefore, it is critical to follow Estonian HIV testing guidelines. More attention is needed in educating health care personnel and ensuring adequate funds for HIV testing.
